NEWS: June 1st, 2017

Vaxon announces results of its Phase IIb lung cancer trial of Vx-001, a therapeutic vaccine based on optimized cryptic peptides

Results for non-small-cell lung cancer patients show that survival more than doubled in a subgroup of never- and light-smokers versus placebo
Vx-001 could also have wider application in cancers
where immune checkpoint inhibitors alone are inefficient

Press release to download – Version Française


VAXON Biotech develops innovative immuno-therapeutic products to treat cancer 

VAXON Biotech is a private company, located in Paris – France, that was founded in 2004. The company develops innovative therapeutic vaccines for the treatment of cancers including lung, gastric, prostate, breast, renal, liver and colorectal cancers, using its proprietary technology of optimized cryptic peptides.

Vaxon Biotech’s therapeutic vaccines are intended to treat existing cancers by stimulating the immune system to recognize and attack human cancer cells without harming normal cells. VAXON’s vaccines utilize proprietary optimized cryptic peptides and target universal tumor antigens that are highly overexpressed in a wide range of tumors while being present in very low quantities in normal tissues.

VAXON has a pipeline of tumor vaccines which cover major HLA-I to treat most cancer patients.

The most advanced vaccine, Vx-001 has completed a 221-patient, double-blind randomized multicentre Phase IIb study in NSCLC. Vx-001 drastically and very significantly prolonged overall survival and time to treatment failure in never and light smokers with non-immunogenic tumors that are not responsive to immune checkpoint inhibitors.

Vx-001 obtained an orphan medicinal product designation for NSCLC from EMA (European Medicines Agency) in November 2007 and from FDA (Food and Drug Administration, US) in February 2009.